Clinical trial NCT00305773: Vorinostat in Treating Patients With Acute Myeloid Leukemia
Official title: A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Adult Acute Erythroid Leukemia (M6)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Promyelocytic Leukemia (M3)
Recurrent Adult Acute Myeloid Leukemia
Refractory Cytopenia With Multilineage Dysplasia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2006-03-22
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving the drug in different ways may kill more cancer cells. This randomized phase II trial is studying two different schedules of vorinostat to see how well they work in treating patients with acute myeloid leukemia.

Detailed description: PRIMARY OBJECTIVES:

I. Determine the toxicity and the proportion of complete remissions associated with two different treatment schedules of vorinostat (SAHA) in patients with acute myeloid leukemia.

SECONDARY OBJECTIVES:

I. Determine the toxic effects of SAHA in this study population. II. Examine for preliminary evidence of re-expression of silenced genes in leukemic blasts in response to SAHA.

OUTLINE: This is a multicenter, randomized study. Patients are stratified according to disease status (relapsed vs untreated). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for up to 2 years.

PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of acute myeloid leukemia (AML), meeting 1 of the following criteria:

  * Relapsed AML in the following categories:

    * Good-risk cytogenetics \[inv(16), t (8;21)\] in second relapse or in first relapse following a remission of \< 12 months
    * Acute promyelocytic leukemia (M3) in second relapse or greater AND must have relapsed following both tretinoin-anthracycline-based therapy and arsenic trioxide-based therapy
    * All other relapsed patients are eligible
  * Untreated AML in the following categories:

    * At least 65 years of age
    * Myelodysplastic syndromes-AML (AML with trilineage dysplasia)
    * AML with del5Q or monosomy 5, monosomy 7, or complex cytogenetics (≥ 3 cytogenetic abnormalities)
* Refused or ineligible for potentially curative options such as allogeneic stem cell transplantation
* No clinical evidence of CNS or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia
* ECOG performance status (PS) 0-2 or Karnofsky PS ≥ 60%
* Life expectancy ≥ 3 months
* Bilirubin normal unless attributed to hemolysis or Gilbert's disease in the opinion of the investigator
* AST/ALT ≤ 2.5 times upper limit of normal (ULN)
* Creatinine normal OR creatinine clearance ≥ 60 mL/min
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
* No uncontrolled intercurrent illness, including any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
  * Psychiatric illness or social situation that would limit compliance with study requirements
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No known HIV positivity
* More than 4 weeks since prior radiotherapy
* More than 2 weeks since prior valproic acid
* More than 3 weeks since other prior treatment for AML, including hematopoietic growth factors

  * Hydroxyurea for WBC \> 30,000/mm\^3 allowed
* Recovered from prior therapy
* No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), epoetin alfa, or darbepoetin alfa
* No other concurrent investigational agents
* No other concurrent anticancer agents or therapies for this cancer

Primary outcomes:
measure: Confirmed Complete Response (CR) Rate
timeFrame: Up to 2 years
Secondary outcomes:
measure: Time to Progression (TTP)
timeFrame: Duration of study (up to 2 years)
measure: Overall Survival (OS)
timeFrame: Duration of study (up to 2 years)
measure: Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events
timeFrame: Duration of study (up to 2 years)
Other outcomes:
measure: Time to Treatment Failure (TTF)
timeFrame: Duration of treatment (up to 17 cycles)
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Steven Gore
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD; Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009 Oct;94(10):1375-82. doi: 10.3324/haematol.2009.009217.